

**Study Number:** I16011  
**Test Type:** TOX  
**Route:** Oral Gavage  
**Species/Strain:** Rat/Harlan Sprague Dawley

**I04: Mean Body Weight Summary**  
**Test Compound:** 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine  
**CAS Number:** 95737-68-1

**Date Report Requested:** 07/18/2023  
**Time Report Requested:** 12:26:34  
**Lab:** Burleson Research Technologies

**Study Number:** I16011  
**Study Gender:** Female  
**PWG Approval Date:** See web page for date of PWG Approval  
**Version:** v1.5.2  
**Stat Version:** v3.0.2A

Study Number: I16011

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

I04: Mean Body Weight Summary

Test Compound: 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

CAS Number: 95737-68-1

Date Report Requested: 07/18/2023

Time Report Requested: 12:26:34

Lab: Burleson Research Technologies

Females: SRBC

Treatment Groups (mg/kg)

Phase Day	0		62.5			125			250		
	Wt (g)	N	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N
SD0	216.4 ± 2.3	12	215.2 ± 3.1	99.4	12	217.4 ± 2.8	100.5	12	216.2 ± 3.2	99.9	12
SD7	225.6 ± 2.5	12	228.8 ± 2.5	101.4	12	225.9 ± 2.5	100.1	12	226.7 ± 3.4	100.5	12
SD14	234.8 ± 2.2	12	235.3 ± 2.6	100.2	12	235.6 ± 2.7	100.4	12	234.7 ± 2.9	100.0	12
SD21	241.2 ± 2.4	12	241.4 ± 2.7	100.1	12	242.3 ± 2.8	100.5	12	240.3 ± 3.0	99.7	12
SD28	245.0 ± 2.7	12	244.8 ± 2.5	99.9	12	244.0 ± 3.6	99.6	12	245.3 ± 3.0	100.1	12

**Study Number:** I16011

**Test Type:** TOX

**Route:** Oral Gavage

**Species/Strain:** Rat/Harlan Sprague Dawley

**I04: Mean Body Weight Summary**

**Test Compound:** 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

**CAS Number:** 95737-68-1

**Date Report Requested:** 07/18/2023

**Time Report Requested:** 12:26:34

**Lab:** Burleson Research Technologies

---

**Females: SRBC**

---

Phase Day	Treatment Groups (mg/kg)					
	500			15 mg/kg CPS		
	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N
SD0	214.9 ± 1.6	99.3	12	219.1 ± 3.8	101.3	8
SD7	223.0 ± 2.0	98.9	12	231.6 ± 2.8	102.7	8
SD14	232.8 ± 1.3	99.2	12	239.4 ± 2.9	102.0	8
SD21	242.4 ± 1.7	100.5	12	248.0 ± 3.0	102.8	8
SD28	244.7 ± 2.1	99.9	12	241.5 ± 3.1	98.6	8

Study Number: I16011

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

I04: Mean Body Weight Summary

Test Compound: 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

CAS Number: 95737-68-1

Date Report Requested: 07/18/2023

Time Report Requested: 12:26:34

Lab: Burleson Research Technologies

Females: KLH

Treatment Groups (mg/kg)

Phase Day	0		62.5			125			250		
	Wt (g)	N	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N
SD0	210.9 ± 3.0	12	214.3 ± 2.6	101.6	12	212.6 ± 3.6	100.8	12	217.4 ± 2.9	103.1	12
SD7	222.3 ± 2.3	12	224.6 ± 2.8	101.0	12	226.2 ± 4.1	101.7	12	226.5 ± 3.0	101.9	12
SD14	233.2 ± 2.8	12	234.9 ± 2.9	100.8	12	234.5 ± 3.2	100.6	12	237.5 ± 4.1	101.9	12
SD21	238.3 ± 2.5	12	240.2 ± 3.1	100.8	12	238.6 ± 3.0	100.1	12	244.1 ± 3.9	102.4	12
SD28	241.3 ± 3.3	12	248.7 ± 3.7	103.0	12	248.0 ± 3.2	102.8	12	251.6 ± 4.0	104.2	12

**Study Number:** I16011

**Test Type:** TOX

**Route:** Oral Gavage

**Species/Strain:** Rat/Harlan Sprague Dawley

**I04: Mean Body Weight Summary**

**Test Compound:** 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

**CAS Number:** 95737-68-1

**Date Report Requested:** 07/18/2023

**Time Report Requested:** 12:26:34

**Lab:** Burleson Research Technologies

---

**Females: KLH**

---

Phase Day	Treatment Groups (mg/kg)					
	500			15 mg/kg CPS		
	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N
SD0	212.5 ± 3.6	100.8	12	211.6 ± 3.0	100.3	8
SD7	221.2 ± 3.4	99.5	12	225.4 ± 2.9	101.4	8
SD14	233.2 ± 3.8	100.0	12	238.0 ± 4.0	102.1	8
SD21	239.7 ± 4.3	100.6	12	233.3 ± 2.5	97.9	8
SD28	244.5 ± 4.3	101.3	12	234.0 ± 2.6	97.0	8

Study Number: I16011

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

I04: Mean Body Weight Summary

Test Compound: 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

CAS Number: 95737-68-1

Date Report Requested: 07/18/2023

Time Report Requested: 12:26:34

Lab: Burleson Research Technologies

Females: KLH Repeat

Treatment Groups (mg/kg)

Phase Day	0		62.5			125			250		
	Wt (g)	N	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N
SD0	207.7 ± 3.2	12	202.2 ± 3.3	97.4	12	203.8 ± 3.2	98.2	12	196.3 ± 3.5	94.5	12
SD7	222.3 ± 3.1	12	216.5 ± 3.4	97.4	12	218.1 ± 3.3	98.1	12	214.0 ± 4.7	96.3	12
SD14	235.1 ± 4.2	12	227.0 ± 3.1	96.6	12	230.6 ± 4.0	98.1	12	225.0 ± 4.9	95.7	12
SD21	241.1 ± 3.6	12	236.2 ± 3.7	98.0	12	241.0 ± 4.2	100.0	12	229.8 ± 4.4	95.3	12
SD28	248.6 ± 2.8	12	240.7 ± 3.4	96.8	12	249.3 ± 4.1	100.3	12	238.0 ± 4.4	95.7	12

**Study Number:** I16011

**Test Type:** TOX

**Route:** Oral Gavage

**Species/Strain:** Rat/Harlan Sprague Dawley

**I04: Mean Body Weight Summary**

**Test Compound:** 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

**CAS Number:** 95737-68-1

**Date Report Requested:** 07/18/2023

**Time Report Requested:** 12:26:34

**Lab:** Burleson Research Technologies

---

**Females: KLH Repeat**

---

Phase Day	Treatment Groups (mg/kg)					
	500			15 mg/kg CPS		
	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N
SD0	202.8 ± 3.0	97.7	12	197.4 ± 4.3	95.0	8
SD7	217.1 ± 4.2	97.7	12	215.3 ± 5.4	96.9	8
SD14	228.8 ± 4.4	97.3	12	226.1 ± 5.0	96.2	8
SD21	234.6 ± 4.5	97.3	12	222.3 ± 5.6 *	92.2	8
SD28	241.7 ± 4.5	97.2	12	220.6 ± 4.9 **	88.8	8

Study Number: I16011

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

I04: Mean Body Weight Summary

Test Compound: 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

CAS Number: 95737-68-1

Date Report Requested: 07/18/2023

Time Report Requested: 12:26:34

Lab: Burlison Research Technologies

Females: Immunophenotyping

Treatment Groups (mg/kg)

Phase Day	0		62.5			125			250		
	Wt (g)	N	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N
SD0	217.2 ± 2.2	12	218.5 ± 2.5	100.6	12	220.8 ± 2.3	101.7	12	220.7 ± 2.2	101.6	12
SD7	227.6 ± 2.1	12	231.1 ± 3.2	101.5	12	229.3 ± 2.6	100.8	12	227.1 ± 2.1	99.8	12
SD14	234.1 ± 2.3	12	238.7 ± 2.8	102.0	12	238.6 ± 3.2	101.9	12	236.4 ± 1.9	101.0	12
SD21	240.2 ± 1.9	12	242.1 ± 2.9	100.8	12	243.5 ± 3.4	101.4	12	241.8 ± 2.2	100.7	12
SD28	245.1 ± 2.4	12	246.9 ± 2.4	100.7	12	247.9 ± 3.3	101.2	12	245.6 ± 2.5	100.2	12

**Study Number:** I16011

**Test Type:** TOX

**Route:** Oral Gavage

**Species/Strain:** Rat/Harlan Sprague Dawley

**I04: Mean Body Weight Summary**

**Test Compound:** 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

**CAS Number:** 95737-68-1

**Date Report Requested:** 07/18/2023

**Time Report Requested:** 12:26:34

**Lab:** Burleson Research Technologies

**Females: Immunophenotyping**

Phase Day	Treatment Groups (mg/kg)					
	500			15 mg/kg CPS		
	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N
SD0	219.4 ± 2.2	101.0	12	220.8 ± 2.6	101.7	8
SD7	227.6 ± 1.9	100.0	12	232.8 ± 3.2	102.3	8
SD14	240.4 ± 2.2	102.7	12	243.9 ± 3.7 *	104.2	8
SD21	244.7 ± 2.3	101.9	12	247.5 ± 3.8	103.1	8
SD28	248.9 ± 1.9	101.6	12	245.6 ± 4.2	100.2	8

Study Number: I16011

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

I04: Mean Body Weight Summary

Test Compound: 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

CAS Number: 95737-68-1

Date Report Requested: 07/18/2023

Time Report Requested: 12:26:34

Lab: Burleson Research Technologies

Females: CTL

Treatment Groups (mg/kg)

Phase Day	0		62.5			125			250		
	Wt (g)	N	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N
SD0	219.0 ± 2.7	12	216.3 ± 2.7	98.7	12	215.8 ± 2.4	98.6	12	214.7 ± 2.2	98.0	12
SD7	226.6 ± 4.6	12	225.9 ± 3.0	99.7	12	224.3 ± 2.1	99.0	12	223.4 ± 3.1	98.6	12
SD14	235.1 ± 4.8	12	231.8 ± 3.1	98.6	12	232.1 ± 2.3	98.7	12	230.3 ± 2.5	98.0	12
SD21	239.0 ± 4.9	12	236.3 ± 3.0	98.8	12	238.8 ± 3.0	99.9	12	238.2 ± 2.8	99.7	12
SD28	241.8 ± 4.5	12	235.7 ± 3.0	97.5	12	238.7 ± 3.0	98.7	12	238.2 ± 2.8	98.5	12

**Study Number:** I16011

**Test Type:** TOX

**Route:** Oral Gavage

**Species/Strain:** Rat/Harlan Sprague Dawley

**I04: Mean Body Weight Summary**

**Test Compound:** 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

**CAS Number:** 95737-68-1

**Date Report Requested:** 07/18/2023

**Time Report Requested:** 12:26:34

**Lab:** Burleson Research Technologies

---

**Females: CTL**

---

Phase Day	Treatment Groups (mg/kg)					
	500			15 mg/kg CPS		
	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N
SD0	218.9 ± 2.7	100.0	12	213.3 ± 3.4	97.4	8
SD7	222.6 ± 3.2	98.2	12	218.3 ± 2.2	96.3	8
SD14	234.5 ± 3.2	99.8	12	225.9 ± 2.4	96.1	8
SD21	240.5 ± 3.8	100.6	12	229.5 ± 2.3	96.0	8
SD28	240.6 ± 3.6	99.5	12	221.8 ± 2.6 **	91.7	8

Study Number: I16011

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

I04: Mean Body Weight Summary

Test Compound: 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

CAS Number: 95737-68-1

Date Report Requested: 07/18/2023

Time Report Requested: 12:26:34

Lab: Burleson Research Technologies

Females: NK

Treatment Groups (mg/kg)

Phase Day	0		62.5			125			250		
	Wt (g)	N	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N
SD0	210.4 ± 3.3	12	209.7 ± 2.4	99.6	12	202.3 ± 2.0	96.1	12	202.5 ± 2.0	96.2	12
SD7	219.7 ± 2.7 *	12	216.7 ± 2.2	98.6	12	212.9 ± 1.9	96.9	12	212.3 ± 2.1	96.6	12
SD14	230.3 ± 3.3	12	228.5 ± 1.7	99.2	12	222.3 ± 2.3	96.6	12	226.4 ± 3.1	98.3	12
SD21	236.0 ± 3.9	12	236.8 ± 2.2	100.4	12	232.6 ± 2.1	98.6	12	235.7 ± 3.3	99.9	12
SD28	235.8 ± 2.7	12	236.1 ± 2.8	100.1	12	229.9 ± 2.1	97.5	12	231.0 ± 2.9	98.0	12

**Study Number:** I16011

**Test Type:** TOX

**Route:** Oral Gavage

**Species/Strain:** Rat/Harlan Sprague Dawley

**I04: Mean Body Weight Summary**

**Test Compound:** 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

**CAS Number:** 95737-68-1

**Date Report Requested:** 07/18/2023

**Time Report Requested:** 12:26:34

**Lab:** Burleson Research Technologies

---

**Females: NK**

---

Phase Day	Treatment Groups (mg/kg)					
	500			15 mg/kg CPS		
	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N
SD0	206.8 ± 3.5	98.3	12	204.0 ± 2.1	97.0	8
SD7	214.7 ± 3.0	97.7	12	218.9 ± 1.9	99.6	8
SD14	229.9 ± 3.6	99.9	12	229.3 ± 2.5	99.6	8
SD21	239.4 ± 3.3	101.4	12	239.1 ± 3.2	101.3	8
SD28	235.7 ± 3.5	100.0	12	224.4 ± 2.5 **	95.2	8

Study Number: I16011

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

I04: Mean Body Weight Summary

Test Compound: 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

CAS Number: 95737-68-1

Date Report Requested: 07/18/2023

Time Report Requested: 12:26:34

Lab: Burlinson Research Technologies

Females: Immunopathology

Treatment Groups (mg/kg)

Phase Day	0		62.5			125			250		
	Wt (g)	N	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N
SD0	209.7 ± 2.7	12	204.0 ± 3.4	97.3	12	201.0 ± 5.1	95.9	12	204.7 ± 3.8	97.6	12
SD5	214.8 ± 3.2	6	207.8 ± 2.6	96.7	6	213.7 ± 2.3	99.5	6	216.8 ± 2.3	100.9	6
SD6	205.8 ± 2.2	6	209.8 ± 3.0	101.9	6	210.8 ± 3.7	102.4	6	215.3 ± 2.8	104.6	6
SD7	215.1 ± 2.2	12	213.2 ± 1.6	99.1	12	218.6 ± 2.3	101.6	12	218.3 ± 1.6	101.5	12
SD14	224.9 ± 2.3	12	224.4 ± 1.8	99.8	12	229.8 ± 2.9	102.2	12	226.3 ± 1.5	100.6	12
SD21	231.8 ± 2.2	12	231.8 ± 2.0	100.0	12	235.8 ± 2.7	101.7	12	238.2 ± 1.8	102.7	12
SD28	238.3 ± 2.5	12	239.0 ± 2.1	100.3	12	242.8 ± 2.2	101.9	12	242.4 ± 2.0	101.7	12

**Study Number:** I16011

**Test Type:** TOX

**Route:** Oral Gavage

**Species/Strain:** Rat/Harlan Sprague Dawley

**I04: Mean Body Weight Summary**

**Test Compound:** 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

**CAS Number:** 95737-68-1

**Date Report Requested:** 07/18/2023

**Time Report Requested:** 12:26:34

**Lab:** Burleson Research Technologies

**Females: Immunopathology**

Phase Day	Treatment Groups (mg/kg)					
	500			15 mg/kg CPS		
	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N
SD0	206.9 ± 2.5	98.7	12	201.6 ± 3.8	96.2	8
SD5	211.2 ± 2.6	98.3	6	214.8 ± 3.1	100.0	4
SD6	213.2 ± 4.7	103.6	6	208.5 ± 2.5	101.3	4
SD7	215.1 ± 2.6	100.0	12	218.3 ± 2.7	101.5	8
SD14	224.9 ± 1.9	100.0	12	230.8 ± 2.4	102.6	8
SD21	234.4 ± 1.9	101.1	12	235.8 ± 2.7	101.7	8
SD28	239.4 ± 2.7	100.5	12	233.9 ± 2.4	98.1	8

**Study Number:** I16011

**Test Type:** TOX

**Route:** Oral Gavage

**Species/Strain:** Rat/Harlan Sprague Dawley

**I04: Mean Body Weight Summary**

**Test Compound:** 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

**CAS Number:** 95737-68-1

**Date Report Requested:** 07/18/2023

**Time Report Requested:** 12:26:34

**Lab:** Burleson Research Technologies

LEGEND

---

Data are displayed as mean  $\pm$  SEM

SD – Study Day

SD – Study Day

Statistical analysis of weight data performed by Jonckheere (trend) and Williams or Dunnett (pairwise) tests.

Statistical analysis for the positive control group compared to the vehicle control group was performed using the t-Test.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

\* Statistically significant at  $P \leq 0.05$

\*\* Statistically significant at  $P \leq 0.01$

CPS = Cyclophosphamide

**\*\* END OF REPORT \*\***